- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
Hepatocellular Carcinoma is the most common primary tumor of liver. It is caused to the people who are having underlying liver diseases such as hepatitis B or C virus, Cirrhosis and non alcoholic fatty liver disease. HCC does not cause any symptoms in the early stages of diseases. Some of the symptoms of HCC includes loss of appetite, weight loss, nausea and vomiting, upper abdominal pain and swelling, jaundice, white and chalky stools etc.
HCC can be prevented by taking hepatitis vaccination. HCC can be diagnosed by blood tests, CT scan, MRI, Liver tissue biopsy. General treatment of HCC includes liver transplantation, surgery, Radiation Therapy, Transcatheter Arterial Chemoembolization, Brachytherapy, Targeted Drug Therapy, Palliative care
Key developments:
- In September 2017, Onxeo S.A released the topline results of phase III Relive trial of Livatag (Doxorubicin Transdrug)in adult patients with unresectablehepatocellular carcinoma (HCC). Results determined that the overall safety and tolerability of Livatag in Relive was favourable with fully manageable toxicity profile in both groups of Livatag20mg/m² and 30mg/m²) and also in patients who has undergone longest treatment period. Thw overall tolerability was comparable to the one observed in comparative group.
- In July 2017, Eisai Inc submitted a supplemental New Drug Application to U.S. FDA for first line use of its lenvatinib (Lenvima) a multiple receptor tyrosine kinaseinhibitor(including fibroblast growth factor receptors [FGFR] 1 4), in patients with hepatocellular carcinoma (HCC).
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Dynamics
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Hepatocellular Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Hepatocellular Carcinoma disease pipeline drugs development. This report studies the dynamics of the Hepatocellular Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Hepatocellular Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
hghNorth America Got Significant Share
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment
Latin America
Europe
Asia Pacific
Middle East
North America
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Segmentation
By Trial Phase
By Company
- Eisai Inc.
- Astellas Pharma Inc
- Pfizer
- Astra Zeneca
- Hoffmann-La Roche
- GlaxoSmithKline
- Oncozyme Pharma Inc.
- Novartis Pharmaceuticals
- Eli Lily & Co
- Bristol-Myers Squibb
By Drugs
- Regorafenib
- SorafenibTosylate
- Lenvatinib
- Sorafenib
- Pentamidine
- Brivanib
- Capecitabine
- Ramucirumab
- Others
By Route of Administration
- Oral
- Parenteral
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1.Executive Summary |
| 2.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Trial Phase |
| 2.2.2.Company |
| 2.2.3.Drugs |
| 2.2.4.Route of Administration |
| 3.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 -2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 5.1. Preclinical Trials |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Phase 1 |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Phase 2 |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Phase 3 |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Phase 4 |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market By Company, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 6.1. Eisai Inc. |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Astellas Pharma Inc |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Pfizer |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Astra Zeneca |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Hoffmann-La Roche |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. GlaxoSmithKline |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Oncozyme Pharma Inc. |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Novartis Pharmaceuticals |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. Eli Lily & Co |
| 6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 6.10. Bristol-Myers Squibb |
| 6.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.10.3. Market Opportunity Analysis |
| 7.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market By Drugs, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 7.1. Regorafenib |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. SorafenibTosylate |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Lenvatinib |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Sorafenib |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Pentamidine |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Brivanib |
| 7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Capecitabine |
| 7.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 7.8. Ramucirumab |
| 7.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.8.3. Market Opportunity Analysis |
| 7.9. Others |
| 7.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 7.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.9.3. Market Opportunity Analysis |
| 8.Global Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Market By Route of Administration, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
| 8.1. Oral |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Parenteral |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9. Competition Landscape |
| 9.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 9.2.1.Eisai Inc. |
| 9.2.2.Astellas Pharma Inc |
| 9.2.3.Pfizer |
| 9.2.4.Astra Zeneca |
| 9.2.5.Hoffmann-La Roche |
| 9.2.6.GlaxoSmithKline |
| 9.2.7.Oncozyme Pharma Inc. |
| 9.2.8.Novartis Pharmaceuticals |
| 9.2.9.Eli Lily & Co |
| 9.2.10.Bristol-Myers Squibb |
| 10. Research Methodology |
| 11. Appendix and Abbreviations |
- Eisai Inc.
- Astellas Pharma Inc
- Pfizer
- Astra Zeneca
- Hoffmann-La Roche
- GlaxoSmithKline
- Oncozyme Pharma Inc.
- Novartis Pharmaceuticals
- Eli Lily & Co
- Bristol-Myers Squibb